People · Operator
Named in public records as an officer, director or promoter · active 2009–2014 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Romark Laboratories, L.C. | — | Pharmaceuticals | Series B | $115.9M | $365.5M | 2009 |
Jean Francois Rossignol at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jean Francois Rossignol on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| W. Andrew Krusen, Jr. | 1 | 4 |
| W. Seymour Holt | 1 | 2 |
| Celine S. Rossignol | 1 | 2 |
| Marc S. Ayers | 1 | 2 |
| Brian S. Schnieders | 1 | 2 |
| Celine Rossignol | 1 | 1 |
| Jeff Crowther | 1 | 1 |
| Jeff B. Crowther | 1 | 1 |
| Brian Schnieders | 1 | 1 |
| Emmet B. Keefe | 1 | 1 |
| Brian E. Schnieders | 1 | 1 |
| Celine E. Rossignol | 1 | 1 |
| Kurt Andrew Frahn | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.